An announcement from Ionis Pharmaceuticals ( ($IONS) ) is now available. On August 21, 2025, Ionis Pharmaceuticals announced that the FDA approved ...

The FDA has granted approval for Ionis Pharmaceuticals’ Dawnzera (donidalorsen), for use in preventing hereditary angioedema ...

On Thursday, the U.S. Food and Drug Administration (FDA) approved Ionis Pharmaceuticals, Inc.’s (NASDAQ:IONS) Dawnzera ...

The U.S. Food and Drug Administration on Thursday approved Ionis Pharmaceuticals' drug to prevent instances of severe ...

Dawnzera is the first and so far only RNA-targeting therapy approved as a prophylactic treatment for hereditary angioedema ...

Since 2008, the FDA has approved 11 treatments for a rare genetic condition called hereditary angioedema (HAE), three of ...

Citi raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $69 from $65 and keeps a Buy rating on the shares following the FDA ...

In June, the monoclonal antibody garadacimab (Andembry) was approved for prevention of HAE attacks at a dose of once monthly ...

Good morning. The Supreme Court is allowing the Trump administration to cut $783 million in research grants tied to DEI work.

In Ionis Pharmaceuticals Inc.’s second U.S. FDA approval in under a year, the agency approved Dawnzera (donidalorsen) as a prophylactic therapy in the rare and genetic disease hereditary angioedema ...

Dawnzera, a prekallikrein-directed antisense oligonucleotide, is supplied as a 80mg/0.8mL solution in a single-dose autoinjector.

Takeda stock steadies after early dip as FDA clears Ionis' Dawnzera for hereditary angioedema, posing fresh competition to Takeda's Takhzyro.